GlassScriptPhysician profile
Riley Lynn Willman
NPI 1043859267
$8,541.95
in general payments reported to CMS, 2019-2025
38 companies · $2,325 in 2025
The $2,325 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $867 · 2022: $1,835 · 2023: $1,208 · 2024: $2,306 · 2025: $2,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,796 · Consulting Fee: $42.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,796.39 |
| Consulting Fee | $42.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,524.40 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Csl Behring | $1,111.51 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $838.75 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $630.55 | 2022-2025 | |
| Optinose US, INC. | $466.56 | 2021-2025 | |
| Genentech USA, INC. | $458.62 | 2021-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $450.29 | 2021-2025 | |
| Grifols USA, LLC | $313.34 | 2022-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $271.86 | 2021-2025 | Cuvitru, Eohilia, Hyqvia |
| Kaleo, INC. | $261.18 | 2021-2024 | Auvi-Q |
| Pharming Healthcare, INC. | $210.26 | 2022-2025 | Ruconest |
| Incyte Corporation | $196.55 | 2022-2023 | Opzelura |
| Pfizer INC. | $190.11 | 2021-2023 | |
| Organon LLC | $172.40 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $142.25 | 2021-2025 | Dupixent |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riley Willman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.